BCL6 anticorps (AA 256-389)
Aperçu rapide pour BCL6 anticorps (AA 256-389) (ABIN5646850)
Antigène
Voir toutes BCL6 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 256-389
-
Purification
- Purified
-
Pureté
- Protein G affinity chromatography
-
Immunogène
- Amino acids 256-389 were used as the immunogen for the Bcl6 antibody.
-
Isotype
- IgG1 kappa
-
-
-
-
Indications d'application
-
Optimal dilution of the Bcl6 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 0.125-0.25 μg/mL,Prediluted IHC only format: incubate for 30 min at RT (1)
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Agent conservateur
- Azide free
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Store the Bcl6 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- BCL6 (B-Cell CLL/lymphoma 6 (BCL6))
-
Autre désignation
- Bcl6
-
Sujet
- Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.
-
Pathways
- Chromatin Binding, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Protein targeting to Nucleus
Antigène
-